PT3326622T - Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática - Google Patents

Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Info

Publication number
PT3326622T
PT3326622T PT171966625T PT17196662T PT3326622T PT 3326622 T PT3326622 T PT 3326622T PT 171966625 T PT171966625 T PT 171966625T PT 17196662 T PT17196662 T PT 17196662T PT 3326622 T PT3326622 T PT 3326622T
Authority
PT
Portugal
Prior art keywords
axl
inhibition
modified
peptides
signaling
Prior art date
Application number
PT171966625T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Univ Leland Stanford Junior
Aravive Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3326622(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior, Aravive Biologics Inc filed Critical Univ Leland Stanford Junior
Publication of PT3326622T publication Critical patent/PT3326622T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT171966625T 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática PT3326622T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
PT3326622T true PT3326622T (pt) 2021-04-07

Family

ID=50934967

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171966625T PT3326622T (pt) 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
PT138627807T PT2931265T (pt) 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT138627807T PT2931265T (pt) 2012-12-14 2013-12-12 Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática

Country Status (11)

Country Link
US (3) US9822347B2 (enExample)
EP (2) EP3326622B1 (enExample)
JP (2) JP6345690B2 (enExample)
AU (3) AU2013359179B2 (enExample)
CA (1) CA2894539C (enExample)
DK (2) DK3326622T3 (enExample)
ES (2) ES2665323T7 (enExample)
FI (1) FI2931265T6 (enExample)
NO (1) NO3049208T3 (enExample)
PT (2) PT3326622T (enExample)
WO (1) WO2014093690A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2556822C2 (ru) * 2010-01-22 2015-07-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Ингибирование axl сигнализации в антиметастатической терапии
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
AU2013359179B2 (en) 2012-12-14 2017-10-05 Aravive Biologics, Inc. Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
WO2016100738A2 (en) * 2014-12-18 2016-06-23 Ruga Corporation Antifibrotic activity of gas6 inhibitor
JP7286179B2 (ja) * 2017-11-04 2023-06-05 アラヴァイヴ バイオロジクス,インコーポレイテッド Axlデコイ受容体を用いる転移性癌の治療方法
KR20240133687A (ko) * 2021-09-11 2024-09-04 아라바이브 인크. 1차 요법으로 axl 유인 수용체를 이용한 국소 진행성 또는 전이성 췌장 선암종의 치료 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030032103A1 (en) 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003304180A1 (en) 2002-09-24 2005-01-04 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
WO2004092735A2 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Axlリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
WO2006058202A2 (en) 2004-11-24 2006-06-01 The Regents Of The University Of Colorado Mer diagnostic and therapeutic agents
CN102191320A (zh) 2005-05-02 2011-09-21 东丽株式会社 用于诊断食管癌的组合物及方法
EP2114983B8 (en) * 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
AU2008240188A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2170395A1 (en) 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
KR20110112299A (ko) * 2008-12-19 2011-10-12 노파르티스 아게 자가면역 및 염증성 장애의 치료에 사용하기 위한 가용성 폴리펩티드
WO2010130751A1 (en) 2009-05-11 2010-11-18 U3 Pharma Gmbh Humanized axl antibodies
RU2556822C2 (ru) 2010-01-22 2015-07-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Ингибирование axl сигнализации в антиметастатической терапии
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
JP6170435B2 (ja) 2010-11-08 2017-07-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変ノッチンペプチドを含む融合タンパク質及びその使用
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
AU2013359179B2 (en) 2012-12-14 2017-10-05 Aravive Biologics, Inc. Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
US20160266136A1 (en) * 2013-08-30 2016-09-15 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
US10137173B2 (en) * 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
WO2016100738A2 (en) * 2014-12-18 2016-06-23 Ruga Corporation Antifibrotic activity of gas6 inhibitor

Also Published As

Publication number Publication date
NO3049208T3 (enExample) 2018-04-14
EP3326622A1 (en) 2018-05-30
CA2894539A1 (en) 2014-06-19
EP2931265B3 (en) 2023-04-05
DK2931265T6 (da) 2023-05-01
AU2017272193A1 (en) 2017-12-21
AU2013359179B2 (en) 2017-10-05
US20150315553A1 (en) 2015-11-05
US11136563B2 (en) 2021-10-05
AU2013359179A1 (en) 2015-07-02
PT2931265T (pt) 2018-04-16
CA2894539C (en) 2021-09-28
ES2665323T3 (es) 2018-04-25
DK2931265T3 (en) 2018-04-16
JP2018154641A (ja) 2018-10-04
JP2016510309A (ja) 2016-04-07
WO2014093690A1 (en) 2014-06-19
EP2931265B1 (en) 2018-01-31
JP6345690B2 (ja) 2018-06-20
FI2931265T6 (fi) 2023-05-23
US9822347B2 (en) 2017-11-21
ES2862335T3 (es) 2021-10-07
DK3326622T3 (da) 2021-04-06
HK1256071A1 (en) 2019-09-13
AU2019210662A1 (en) 2019-08-22
AU2019210662B2 (en) 2021-07-01
JP6832887B2 (ja) 2021-02-24
EP2931265A4 (en) 2016-08-31
EP3326622B1 (en) 2021-01-20
US20180030422A1 (en) 2018-02-01
EP2931265A1 (en) 2015-10-21
ES2665323T7 (es) 2023-06-15
US20220220458A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
ZA201307676B (en) Inhibition of axl signaling in anti-metastatic therapy
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
GB201218862D0 (en) Bicyclic heterocycle compounds and their uses in therapy
ZA201307797B (en) Bicyclic heterocycle compounds and their uses in therapy
SG10201707020TA (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
PT3326622T (pt) Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
GB201218850D0 (en) Bicyclic heterocycle compounds and their uses in therapy
SG10201609940RA (en) Compounds and their methods of use
GB201218864D0 (en) Bicyclic heterocycle compounds and their uses in therapy
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
EP2806811A4 (en) VERTEBRAL CONSTRUCTION
IL233481A0 (en) Peptides and methods of using them
EP2872208A4 (en) SLEEPING SUPPORTING ARTICLE AND METHOD OF APPLICATION THEREFOR
PL2922557T3 (pl) Suplementy ziołowe i sposoby ich zastosowania
IL234841A0 (en) Administration forms of halofuginone and methods of use
PL2667880T3 (pl) Oligopeptydy metaloproteinaz i ich zastosowanie terapeutyczne
PL2790666T3 (pl) Ekstrakty z maesa japonica i sposoby zastosowania
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
ZA201306861B (en) Outlet fitting basic body and outlet body therefor
GB201219678D0 (en) Ketone body inhibitors and uses thereof
EP2836227A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
PL2744497T3 (pl) Terapeutyczne połączenia netupitantu i palonosetronu
EP2877486A4 (en) PEPTIDE-BASED COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BETA-AMYLOID ACCUMULATION